2026.07.30

XI News | Wishing Shanghai Xichang Bio a happy third anniversary!

Thank you for being with us—hand in hand, we’ve witnessed 1,095 days, from the moment the seed was first planted to the tender sprout that has now emerged. Over the course of three years, the seed sown long ago has quietly begun to bud.

2026.01.29

XI News | Xichang Bio and Xunmeng Bio Have Reached a Strategic Partnership, Jointly Ushering in a New Chapter!

On January 25, 2026, at the launch ceremony of “OriStar,” a startup community for young biomedical scientists initiated by the Haihuo Tiancheng Club, Dr. Tao Weihong, Founder and CEO of Xichang Bio, and Dr. He Yusheng, Founder and CEO of Xunmeng Bio, formally signed a strategic cooperation agreement on behalf of their respective companies. This marks the beginning of a new chapter in which these two innovative enterprises, both deeply rooted in the biopharmaceutical sector, will join forces to pursue technological synergy and mutually beneficial growth.

2025.12.04

XI News | Xichang Bio Has Successfully Been Recognized as a National High-Tech Enterprise!

Good news keeps pouring in—another honor has been bestowed! After rigorous review and a period of public announcement, Xichang Bio has officially been certified as a National High-Tech Enterprise, earning this prestigious national-level accreditation that underscores the company’s innovative strength.

2025.12.03

XI News | Xichang Bio has made the list of winners in the Startup Category of “Innovation·Shanghai 2025,” returning home with honors!

Recently, the finals of the 2025 “Innovation·Shanghai” International Innovation and Entrepreneurship Competition concluded successfully! Shanghai Constream biotechnology Co., Ltd. stood out among numerous outstanding enterprises with its cutting-edge technological achievements, a clear commercialization roadmap, and strong growth potential, securing third place in the Startup Category and earning industry recognition and prestigious accolades through its exceptional performance.

2025.11.11

XI News | Xichang Bio Wins the Grand Prize in the Startup Category of “Innovation·Shanghai 2025”!

Recently, at the 2025 “Innovation · in Shanghai” International Innovation and Entrepreneurship Competition, the official list of winners was announced. Shanghai Constream biotechnology Co., Ltd. stood out from thousands of participating projects with its robust capabilities and innovative potential in the field of antibody drug development, earning the title of Outstanding Enterprise in the Startup Category!

2025.08.18

Xi News | Xichang Bio’s Asia BIO Singapore Summit Concludes Successfully!

On August 14–15, 2025, the Asia BIO Innovation Summit 2025—the most influential industry event in Asia’s biopharmaceutical sector—concluded successfully in Singapore. Centered on antibody‑drug conjugates (ADCs) and cell and gene therapies (CGTs), this global summit brought together leading pharmaceutical companies, research institutions, and investment firms from across Asia and around the world, serving as a vital platform for cutting‑edge technological exchange, insights into industry trends, and strategic business collaborations. As an innovative force deeply engaged in antibody discovery and early‑stage R&D, Xichang Bio was invited to attend and delivered a keynote presentation on August 15, joining its global peers in exploring pathways to technological breakthroughs and co‑creating a vision for biopharmaceutical innovation.

2025.08.26

Xi News | Xichang Bio has successfully advanced to the Qingpu regional semifinals of the 2025 “Innovation·Shanghai” International Innovation and Entrepreneurship Competition!

On August 25, 2025, the Science and Technology Commission of Qingpu District, Shanghai, officially released the “Public Notice on Enterprises Advancing to the Semifinals of the Qingpu Division of the 2025 ‘Innovation·Shanghai’ International Innovation and Entrepreneurship Competition.” Relying on its technological strength and innovative potential in the field of antibody drug development, Shanghai Constream biotechnology Co., Ltd. stood out among numerous participating enterprises and was successfully selected for the semifinalist list (listed as item 20 in the attachment, belonging to the Startup Group), marking official recognition of the company’s technological direction and development prospects.

2025.08.13

Xi News | Xichang Bio has been invited to attend the Asia BIO Singapore event—August 14–15, focusing on the two cutting-edge fields of ADCs and CGTs.

The Asia BIO Innovation Summit 2025 is one of the most influential industry events in Asia, with a strong focus on two cutting-edge fields: antibody–drug conjugates (ADCs) and cell and gene therapies (CGTs). The summit aims to establish an academic exchange platform, enabling leading ADC and CGT companies from Asia and around the world to showcase their latest technologies and research findings, while fostering in-person international technical exchanges and facilitating business collaboration opportunities.

2025.06.05

XI News | Joining Forces for a Grand Event, Riding High on Prestige! CGCS 2025 Concludes Successfully, with Shanghai Xichang Bio Honored with the Rising Star Award.

On May 29–30, 2025, the “CGCS 2025 Sixth International China Summit and Exhibition on Cell and Gene Therapy,” hosted by Chujie Bio, was grandly held at the Nanjing Yangtze River International Convention Center. Shanghai Xichang Bio, a key player in the cell and gene therapy (CGT) sector, attended this major industry event, engaging with global experts and industry leaders to discuss cutting-edge trends.

2025.05.21

XI News | Exploring the Timeless Charm of Water Towns, Strengthening Team Spirit — A Special Feature on Team Building

On May 16, under a gentle breeze and dappled clouds, all members of our company set out together for Zhouzhuang Ancient Town, renowned as “China’s First Water Town.”